Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding

International Journal of Cancer

Volumn 104, Issue 1, 2003, Pages 85-91

  Airley, Rachel E ^a,b,e   Loncaster, Juliette ^b   Raleigh, James A ^c   Harris, Adrian L ^d   Davidson, Susan E ^b   Hunter, Robert D ^b   West, Catharine M L ^b   Stratford, Ian J ^e  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CAIX; Glut 1; Hypoxia; Pimonidazole

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; PIMONIDAZOLE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RESISTANCE; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; OXYGEN TENSION; PRIORITY JOURNAL; RADIOSENSITIVITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ADULT; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIOPSY; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; DNA-BINDING PROTEINS; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICROELECTRODES; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASM PROTEINS; NITROIMIDAZOLES; NUCLEAR PROTEINS; OBSERVER VARIATION; OXYGEN; PARTIAL PRESSURE; RADIATION-SENSITIZING AGENTS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0037430244     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10904     Document Type: Article

References (57)

1. Vaupel P, Hoeckel M. Predictive power of the tumor oxygenation status. Adv Exp Med Biol 1999;471:533-9.
2. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
3. Hall EJ. Radiobiology for the radiologist, 5th ed. Philadelphia: Lippincott, 1998.
4. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
5. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
6. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
7. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;45:149-56.
8. Sundfor K, Lyng H, Trope CG, Rofstad EK. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationship to pre-treatment tumor oxygenation and vascularization. Radiother Oncol 2000;54:101-7.
9. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;21:266-76.
10. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Ean JM, Prosnitz LR. Tumor oxygenation predicts the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
11. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
12. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78:822-7.
13. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 1988;85:9533-7.
14. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia A. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
15. Overgaard J, Horsman MR. Modification of hypoxia-induced radio-resistance in tumours by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
16. Vaupel P, Kelleher DK. Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1999.
17. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with Carbogen of varying carb concentrations. Radiother Oncol 1999;50:167-71.
18. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti Cancer Drug Design 1998;13:519-28.
19. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL. Targeting gene expression to hypoxic tumour cells. Nat Med 1997;3:515-20.
20. Kallinowski F, Zander R, Hoeckel M, Vaupel P. Tumor tissue oxygenation as evaluated by computerized pO2-histography. Int J Radiat Oncol Biol Phys 1990;19:953-61.
21. Chapman JD. Measurement of tumor hypoxia by invasive and noninvasive procedures: a review of recent clinical studies. Radiother Oncol 1991;20(Suppl):13-9.
22. Raleigh JA, Miller GG, Franko AJ, Koch CJ, Fuciarelli AF, Kelly DA. Fluorescence Immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 1987;56:395-400.
23. Raleigh JA, Calkins-Adams DP, Rinker LH, Ballenger CA, Weissler MC, Fowler WC Jr, Novotny DB, Varia MA. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998; 58:3765-8.
24. 1H-imidazol-l-yl)-N-(2,2,3,3, 3-pentafluropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869-74.
25. Hodgkiss RJ, Webster L, Wilson GD. Measurement of hypoxia in vivo using a 2-nitroimidazole (NITP). Adv Exp Med Biol 1997;428: 61-7.
26. Aboagye EO, Kelson AB, Tracy M, Workman P. Preclinical development and current status of the fluorinated 2-nitroimidaz N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-l-imidazolyl)acetamide (S non-invasive diagnostic probe for the measurement of tumour hypoxia by spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des 1998;13:703-30.
27. Raleigh JA, Franko AJ, Treiber EO, Lunt JA, Allen PS. Covalent binding of a fluorinated2-nitroimidazole to EMT-6 tumours in BALB/c mice: detection by F-19 nuclear magnetic resonance at 2.35 T. Int J Radiat Oncol Biol Phys 1986;12:1243-5.
28. 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1989; 16:925-9.
29. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56:405-11.
30. Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, Varia MA. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997;37:897-905.
31. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, Raleigh JA. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998;71:270-7.
32. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lingegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001;49:581-6.
33. Maxwell PH, Pugh CW, Ratcliffe PJ Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 1993;90:2423-7.
34. Forsythe JA, Jiang BH, Iyer NV, Agani N, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia- inducible factor 1. Mol Cell Biol 1996;16: 4604-13.
35. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expressions of glucose transporter, via distinct cis-acting sequences. J Biol Chem 1995;270:29083-9.
36. Wykoff CC, Bleasley NJP, Watson PH, Turner KJ, Pastorak J, Sibtain A, Wilson GD, Turley H, Talks KL. Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
37. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C. Glucose transporter Glut-1 expression correlates with tumour hypoxia and predicts metastasis free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7:928-34.
38. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CML. CAIX expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.
39. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada JA. Novel quasi-viral agent, Ma Tu, is a two-component system. Virology 1992;187:620-6.
40. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumours. Int J Radiat Oncol Biol Phys 2001;49:569-74.
41. Airley RE. Hypoxia-regulated glucose transport in tumours: individualization of bioreductive chemotherapy using facilitative glucose transporters as surrogate markers of hypoxia. Ph.D. thesis. University of Manchester, 2001. 167-71.
42. Warburg O. The metabolism of tumours. London: Onstable, 1930.
43. Younes M, Brown RW, Stephenson M. Overexpression of Glut-1 and Glut-3 in stage 1 non-small cell lung carcinoma is associated with poor survival. Cancer 1997;50:1046-51.
44. Harber RS, Rathan A, Weiser KR, Pritsker KR, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE. Glut-1 glucose transporter expression in colorectal carcinoma. Cancer 1998;83:34-40.
45. Cartiana G, Fagotti G, Megathaes A, Nadji M, Angioli R, Panalver M. Mancuso S, Scambia G. Glut-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001; 92:1144-50.
46. Price P. Positron emission tomography (PET) in diagnostic oncology: is it a necessary tool today? Eur J Cancer 2000;36:691-3.
47. Pastorek J, Pastorekova S, Callebaut I, Momon JP, Zelnik V, Opavsky R, Zat'ovicova M, Liao S, Portetelle D, Stanbridge EJ. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loophelix DNA binding segment. Oncogene 1994;9:2877-88.
48. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorak J, Garter KC, Ratcliffe P, Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX in invasive breast carcinoma. J Clin Oncol 2001;19:3660-8.
49. Giatromanolaki A, Koukourakis MI, Sivndis E, Simopoulos K, Pastorak J, Wycoff CC, Gatter KC, Harris AL. Expression of hypoxiainducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-8.
50. Koukarakis MI, Giatronianolaki A, Sivndis E. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
51. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumour vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 2001;61:2907-10.
52. Raleigh JA, Koch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol 1990;40: 2457-64.
53. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumour response to fractionated radiotherapy. Radiat Res 1997;47:541-50.
54. Haugland HK, Vukovic V, Pintilie M, Fyles A W, Milosevic M, Hill RP, Hedley DW. Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:854-61.
55. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raliegh JA, Lerman MI, Stanbridge EJ. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61: 8924-9.
56. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
57. Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-8.